Welcome to our dedicated page for Nuvalent news (Ticker: NUVL), a resource for investors and traders seeking the latest updates and insights on Nuvalent stock.
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company developing precisely targeted kinase inhibitors for oncogene-driven cancers, with a focus on non-small cell lung cancer (NSCLC). The NUVL news feed on Stock Titan aggregates company announcements, press releases, and related coverage so readers can follow how its pipeline and regulatory interactions progress over time.
According to Nuvalent’s disclosures, its lead investigational programs include zidesamtinib, a ROS1-selective inhibitor for ROS1-positive NSCLC, and neladalkib, an ALK-selective inhibitor for ALK-positive NSCLC. News items often highlight pivotal and preliminary data from the ARROS-1 and ALKOVE-1 Phase 1/2 trials, updates on the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC, and information about design features such as brain penetrance and activity against resistance mutations.
Investors and observers can also find coverage of Nuvalent’s regulatory milestones, including FDA breakthrough therapy and orphan drug designations, New Drug Application (NDA) submissions and acceptances, and PDUFA target action dates. Corporate developments such as public equity offerings, cash runway guidance, royalty arrangements on future net sales of zidesamtinib and neladalkib, and board appointments are regularly disclosed through press releases and Form 8-K filings and are reflected in the news flow.
For those tracking NUVL, this news stream provides a centralized view of clinical trial readouts, conference presentations, financing activities, and strategic updates that shape the company’s outlook in targeted oncology. Bookmarking the NUVL news page on Stock Titan can help readers quickly review new disclosures and place them in the context of Nuvalent’s broader development strategy.
Nuvalent, Inc. (Nasdaq: NUVL) has appointed Anna Protopapas as the new Chair of its Board of Directors, transitioning from Cameron Wheeler, who remains on the board. Protopapas brings extensive executive experience in oncology, having previously led Mersana Therapeutics and Millennium Pharmaceuticals. The company is currently enrolling patients in its Phase 1 ARROS-1 study for NVL-520, a ROS1-selective inhibitor, and has cleared an Investigational New Drug application for NVL-655, an ALK-selective inhibitor, expecting to initiate clinical trials soon.
Nuvalent (NASDAQ: NUVL) announced the FDA's clearance of its IND application for NVL-655, aimed at treating ALK-positive NSCLC. The company plans to initiate the ALKOVE-1 Phase 1/2 trial in Q2 2022. Additionally, enrollment is ongoing in the ARROS-1 trial for NVL-520, targeting advanced ROS1-positive NSCLC. The firm reported cash and equivalents of $288.1 million as of Dec 31, 2021, sufficient to fund operations into 2024. R&D expenses were $35.6 million for 2021, while the net loss was $46.3 million. Nuvalent expects to nominate additional product candidates in 2022.
Nuvalent, Inc. (Nasdaq: NUVL) announced the presentation of preclinical data for its lead programs, NVL-520 and NVL-655, at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. NVL-520 is a ROS1-selective inhibitor targeting advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors, currently under investigation in a Phase 1/2 study. NVL-655 is an ALK-selective inhibitor aimed at overcoming resistance in ALK-positive cancers, with a clinical trial planned for 2022. Both are designed to improve treatment outcomes in cancer patients.
Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company specializing in targeted cancer therapies, will have CEO James Porter participate in the 'Lung Cancer Panel' at the Cowen 42nd Annual Healthcare Conference on March 9, 2022, at 9:10 a.m. ET. The event will be accessible via a live webcast on the company's investor website, which will be archived for 30 days. Nuvalent is advancing treatments for ROS1-positive and ALK-positive non-small cell lung cancer, focusing on overcoming existing therapy limitations.
Nuvalent, Inc. (Nasdaq: NUVL) announced the appointment of Emily Drabant Conley, Ph.D., CEO of Federation Bio, to its Board of Directors. Dr. Conley brings extensive experience in genomics and diagnostics, having previously contributed to 23andMe's growth. Her expertise aligns with Nuvalent's focus on developing targeted cancer therapies and enhancing their clinical trial operations, including the ongoing ARROS-1 study for NVL-520. This strategic appointment aims to strengthen leadership as Nuvalent transitions into a clinical-stage company, focusing on advanced cancer treatments.
Nuvalent, Inc. announced the first patient has been dosed in the Phase 1/2 clinical trial ARROS-1, evaluating NVL-520 for advanced ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a selective ROS1 inhibitor designed to tackle treatment resistance and CNS adverse effects. The trial aims to establish safety, tolerability, and efficacy in patients previously treated with ROS1 inhibitors. With $288.4 million in cash, Nuvalent expects to fund operations into 2024, focusing on their development pipeline, including NVL-655.
Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical firm, will be presenting at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 a.m. ET. CEO James Porter, Ph.D., will lead the presentation, highlighting the company's focus on precisely targeted therapies for cancer.
The event will be accessible via a live webcast on the company's investor website and archived for 30 days. Nuvalent specializes in developing innovative small molecules aimed at overcoming therapeutic limitations in patients with ROS1-positive and ALK-positive non-small cell lung cancer.
Nuvalent, Inc. (Nasdaq: NUVL) announced its third quarter 2021 financial results, showcasing advancements in its oncology pipeline. The company reported a cash position of $302.4 million, reflecting growth since 2020. Operating expenses were $12.4 million, up from $4 million in Q3 2020, contributing to a net loss of $12.4 million or $0.39 per share. Notably, the Phase 1/2 ARROS-1 trial for NVL-520 is open for enrollment, targeting ROS1-positive non-small cell lung cancer, with plans for further clinical development of NVL-655 for ALK-positive cancers.
Nuvalent, Inc. (Nasdaq: NUVL) has released new preclinical data for its lead programs, NVL-520 (ROS1-selective inhibitor) and NVL-655 (ALK-selective inhibitor), focusing on non-small cell lung cancer. The data, presented at the AACR-NCI-EORTC Conference, indicates that both drug candidates are effective against known resistance variants and are brain-penetrant, addressing a critical challenge in cancer therapy. Additionally, the FDA cleared NVL-520 for clinical trials, which are set to begin in late 2021 and early 2022 for NVL-655. This progress is anticipated to enhance the durability of treatment responses in patients.
Nuvalent, Inc. (Nasdaq: NUVL) announced significant advancements in its pipeline and reported second-quarter 2021 financial results. The FDA cleared the IND application for its ROS1-selective inhibitor NVL-520, enabling a Phase 1/2 clinical trial to begin in late 2021. The company completed a $190.6 million IPO in July 2021, enhancing its financial position, with cash on hand of $138.9 million as of June 30, 2021. The net loss for Q2 2021 was $9.8 million, or $3.17 per share. Nuvalent continues to invest in its research and development efforts, targeting precision therapies for cancer.